Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Mistelbach – page 31

889 clinical trials in Mistelbach, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mistelbach at a glance
889
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

889 trials in Mistelbach

Open in trial search

Triple negative breast cancer+3

Not yet recruiting

Evaluation of DOTATATE and GOZETOTIDE for Diagnosis and Treatment in Patients with Solid Tumors and Brain Metastases

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dotatate
  • Sponsor:Medica Scientia Innovation Research S.L.

Efficacy of neoadjuvant sacituzumab govitecan versus standard drug combination in patients with endocrine non‑responsive ER+/HER2‑negative early breast cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group

Cutaneous sarcoidosis

Not yet recruiting

A Phase 2/3 Study of the Safety and Efficacy of Oral Brepocitinib in Adults with Cutaneous Sarcoidosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Brepocitinib Tosilate
  • Sponsor:Priovant Therapeutics Inc.

Multiple sclerosis

Not yet recruiting

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Prostate cancer metastatic

Not yet recruiting

Study of saruparib plus AR inhibitor drug combination in men with metastatic hormone‑sensitive prostate cancer previously treated with docetaxel or Lu‑PSMA and PSA ≥0.2 ng/mL

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Astrazeneca AB

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Cardiac amyloidosis

Not yet recruiting

Serum Transthyretin Levels in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis and Acoramidis: A Within‑Patient Pilot Crossover Study

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis
  • Sponsor:Medical University Of Vienna

Psychotic disorder+2

Not yet recruiting

A Randomized Controlled Trial of Cannabidiol vs Placebo Augmentation in Patients with First Episode Psychosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Cannabidiol
  • Sponsor:University Of Oxford

Non-small cell lung cancer

Not yet recruiting

Ivonescimab with drug combination in patients with asymptomatic brain metastases from non‑small cell lung cancer – randomized phase II trial

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi

Sjogren's syndrome

Not yet recruiting

A Phase 2a/b Study of DDY391 to Evaluate Efficacy, Safety and Tolerability in Adults with Sjögren's Disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Mistelbach

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking studies focusing on stroke prevention and management of atrial fibrillation. Research evaluates innovative treatments comparing asundexian to established medications for reducing stroke risk in patients with irregular heartbeat.

  • Stroke Prevention
  • Atrial Fibrillation Management
  • Systemic Embolism Prevention

Trials aim to assess both effectiveness and safety profiles of new therapeutic approaches.

02 Oncology Studies

Advanced research in breast cancer treatment, specifically focusing on hormone receptor-positive/HER2-negative early breast cancer. Studies evaluate the effectiveness of combining palbociclib with standard endocrine therapy.

  • Early Breast Cancer Treatment
  • Endocrine Therapy Enhancement
  • Disease-Free Survival Assessment

Research aims to improve treatment outcomes through innovative combination therapies.

03 Neurology Research

Innovative studies examining treatments for acute ischemic stroke and high-risk transient ischemic attacks. Research evaluates the efficacy of milvexian in reducing stroke risk compared to placebo.

  • Acute Stroke Treatment
  • Ischemic Attack Prevention
  • Neurological Recovery

Focus on developing more effective interventions for stroke prevention and management.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.